304854-32-8

Basic information

• Product Name: 6-(2,3-Difluoro-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
• CAS NO: 304854-32-8
• Molecular Weight: 289.282
• Mol File: 304854-32-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 6-(2,3-Difluoro-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(2,3-Difluoro-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one(304854-32-8)
• EPA Substance Registry System: 6-(2,3-Difluoro-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one(304854-32-8)

Safety Data

• Hazardous Substances Data: 304854-32-8(Hazardous Substances Data)

Upstream product

• 304854-57-7 2,3-difluorobenzyltriflate 
• 304853-90-5 (1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)boronic acid 

Relevant articles and documents

Combination regimens using progesterone receptor modulators

This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure: wherein R1and R2may be single substituents or fused to form spirocyclic or hetero-spirocyclic rings; R3is H, OH, NH2, C1to C6alkyl, substituted C1to C6allyl C3to C6alkenyl, substituted C1to C6alkenyl, alkynyl, or substituted alknyl, CORC; RCis H, C1to C3alkyl, substituted C1to C3alkyl, aryl, substituted aryl, C1to C3alkoxy, substituted C1to C3alkoxy, C1to C3aminoalkyl, or substituted C1to C3aminoalkyl; R4is H, halogen, CN, NO2, C1to C6alkyl, substituted C1to C6alkyl alkynyl, or substituted alkynyl, C1to C6alkoxy, substituted C1to C6alkoxy, amino, C1to C6aminoalkyl, or substituted C1to C6aminoalkyl; and R5is selected from a trisubstituted benzene ring of a five or six membered ring with 1, 2, or 3 heteroatoms from the group including O, S, SO, SO2or NR6and containing one or two independent substituents from the group including H, halogen, CN, NO2, amino, and C1to C3alkyl, C1to C3alkoxy, C1to C3aminoalkyl, CORF, or NRGCORF; or pharmaceutically acceptable salt thereof. These methods of treatment may be used for contraception or for the treatment and/or prevention of secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, or inmization of side effects or cyclic menstrual bleeding. Additional uses of the invention include stimulation of food intake.

Cyclocarbamate derivatives as progesterone receptor modulators

This invention provides compounds of Formula (I): wherein R1 and R2 may be single substituents or fused to form spirocyclic or hetero-spirocyclic rings; R3 is H, OH, NH2, C1 to C6 alkyl, substituted C1 to C6 alkyl, C3 to C6 alkenyl, substituted C1 to C6 alkenyl, alkynyl, or substituted alkynyl, CORC; RC is H, C1 to C3 alkyl, substituted C1 to C3 alkyl, aryl, substituted aryl, C1 to C3 alkoxy, substituted C1 to C3 alkoxy, C1 to C3 aminoalkyl, or substituted C1 to C3 aminoalkyl; R4 is H, halogen, CN, NO2, C1 to C6 alkyl, substituted C1 to C6 alkyl, alkynyl, or substituted alkynyl, C1 to C6 alkoxy, substituted C1 to C6 alkoxy, amino, C1 to C6 aminoalkyl, or substituted C1 to C6 aminoalkyl; and R5 is selected from a trisubstituted benzene ring of a five or six membered ring with 1, 2, or 3 heteroatoms from the group including O, S, SO, SO2 or NR6 and containing one or two independent substituents from the group including H, halogen, CN, NO2, amino, and C1 to C3 alky, C1 to C3 alkoxy, C1 to C3 aminoalkyl, CORF, or NRGCORF; or pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions and methods using the compounds as antagonists of the progesterone receptor.